Test Price
2,300 AED✅ Home Collection Available
Genetic Mapping for Cardiovascular Disorders in UAE | 2,300 AED | 2026 DHA Guidelines
التحليل الجيني لاضطرابات القلب والأوعية الدموية في الإمارات | 2,300 درهم | معتمد من هيئة الصحة بدبي
Executive Summary — Genetic Cardiovascular Risk Stratification
الملخص التنفيذي: يوفر اختبار التحليل الجيني لاضطرابات القلب والأوعية الدموية تقييماً شاملاً للطفرات الجينية المرتبطة بأمراض القلب الوراثية باستخدام تقنية المصفوفات الدقيقة للكروموسومات (Chromosomal Microarray) وطرق التنميط الجيني المتقدمة (SNP Genotyping). تُحلل العينة في مختبراتنا المعتمدة وفق شهادة الآيزو 9001:2015، مع ضمان دقة تشخيصية تصل إلى 99.9%. يتوفر هذا الفحص في جميع إمارات الدولة مع خدمة سحب العينات المنزلية المدفوعة وفق معايير النقل المبرد المعتمدة، ويتضمن استشارة طبية هاتفية بعد صدور النتائج لتفسيرها إكلينيكياً.
Diagnostic Sensitivity
99.9%
ISO-Accredited Microarray Processing
Sample Collection
Hospital-Grade Home Service
ISO-Certified Cold Chain Logistics, 8 AM – 11 PM
Post-Test Guidance
Telephonic Clinical Correlation
Expert Interpretation by DHA-Licensed Cardiologist
Insurance Verification
Direct Billing Support
WhatsApp: +971 54 548 8731
1. Test Overview — Genetic Mapping for Cardiovascular Disorders
Genetic Mapping for Cardiovascular Disorders is a high-resolution genomic screening test that analyzes single nucleotide polymorphisms (SNPs) and chromosomal copy number variations associated with inherited cardiac conditions, including cardiomyopathies, arrhythmogenic disorders, and familial hyperlipidemias. This 2,300 AED panel delivers clinically actionable insights for cardiologists, sports scientists, and precision-medicine researchers seeking to identify latent cardiovascular risk before phenotypic manifestation.
التحليل الجيني لاضطرابات القلب والأوعية الدموية هو فحص جينومي عالي الدقة يُحدد التغيرات الجينية المرتبطة بأمراض القلب الوراثية، مما يتيح التدخل المبكر والوقاية الشخصية.
| Parameter | Our Test — Chromosomal Microarray + SNP Genotyping | Traditional Single-Gene Sequencing | Standard Lipid Panel Only |
|---|---|---|---|
| Genomic Coverage | Genome-wide SNPs + CNVs across all known cardiovascular loci | Limited to one or few targeted genes (e.g., LDLR only) | No genetic data; biochemical phenotype only |
| Methodology | High-Density SNP Microarray + LC-MS/MS Validation | Sanger Sequencing / NGS Panel | Enzymatic Colorimetric / Turbidimetric |
| Turnaround Time | 8 Weeks (Comprehensive Analysis & Clinical Annotation) | 4–6 Weeks | Same Day |
| Clinical Utility | Predictive, Diagnostic & Prognostic — Polygenic Risk Scoring | Diagnostic for monogenic disorders only | Screening only; no genetic risk stratification |
| Price (UAE) | 2,300 AED | 1,500–4,000 AED (per gene) | 150–300 AED |
2. Physician Insight & Clinical Safety Protocol
Dr. Prabhakar Reddy — Consultant Interventional Cardiologist, DHA License 61713011
"Genetic mapping does not replace clinical judgment — it empowers it. Every result from this cardiovascular genomic panel must be interpreted within the full context of your personal and family history, physical examination, and complementary investigations such as echocardiography and lipid profiling. I have seen these insights transform patient outcomes when used responsibly. However, a 'negative' genetic report does not eliminate cardiovascular risk, and a 'positive' finding requires thoughtful, evidence-based clinical correlation before any intervention."
CRITICAL MEDICATION NOTICE:
Do not discontinue, adjust, or initiate any prescribed cardiovascular medication — including statins, antihypertensives, antiarrhythmics, or anticoagulants — based solely on genetic mapping results. Always consult your treating cardiologist or prescribing physician before making any changes to your medication regimen. Genetic predisposition is only one factor in a multifactorial disease process.
Patient Safety: Exclusion Criteria & Emergency Red Flags
Exclusion Criteria — Do NOT proceed with home collection if:
- Patient is currently hospitalized or in an acute care setting.
- Active febrile illness with temperature exceeding 38.5°C within the last 48 hours.
- Known active hematological malignancy or recent bone marrow transplant (within 90 days).
- Patient is a minor (under 18 years) without a legally authorized guardian's signed consent per UAE CDS Law 2026.
- Incomplete or unsigned Genome Mapping Consent Form (Form 26).
- Recent whole blood transfusion (within 4 weeks) — may cause chimerism artifacts.
Emergency Red Flags — Seek immediate medical attention if you experience:
- Chest pain, pressure, or discomfort radiating to the arm, jaw, or back.
- Syncope (fainting) or near-syncope, especially during exertion.
- Palpitations accompanied by shortness of breath or dizziness.
- Unexplained dyspnea, orthopnea, or paroxysmal nocturnal dyspnea.
- Family history of sudden cardiac death under age 50 — do not wait for genetic results.
If you experience any of these symptoms, call 998 (UAE Ambulance) or proceed to the nearest Emergency Department immediately. Genetic testing is an elective preventive tool and is not appropriate during acute clinical events.
3. Specimen Requirements & Pre-Test Information
| Sample Type | 3 mL (2 mL minimum) whole blood in 1 Lavender Top (EDTA) tube |
| Transport Condition | Ship refrigerated (2–8°C). DO NOT FREEZE. |
| Cut-off Time | Sample accepted daily by 9:00 AM GST |
| Turnaround Time | 8 Weeks (comprehensive genomic analysis, annotation, and clinical report generation) |
| Mandatory Requirement | Duly filled and signed Genome Mapping Consent Form (Form 26) is mandatory. Samples received without a completed Form 26 will be rejected and require recollection. |
| Price | 2,300 AED |
Pre-Test Advisory — Medication & Supplement Awareness:
Inform your phlebotomist of all current medications, including anticoagulants (e.g., warfarin, apixaban, rivaroxaban), antiplatelet agents (e.g., clopidogrel, ticagrelor), and high-dose omega-3 fatty acid supplements. While these do not invalidate genetic testing, they may affect sample integrity for any concurrent biochemical analyses. No medication should be discontinued without explicit physician approval.
4. UAE Regulatory Compliance & Data Privacy Assurance
This laboratory service operates under the full regulatory framework of the United Arab Emirates. All genetic testing is conducted in strict compliance with:
- Federal Decree-Law No. 41 of 2024 (Article 87) — Regulation of genetic testing services, mandating informed consent, clinical validity, and prohibition of genetic discrimination.
- UAE Communicable Disease Surveillance (CDS) Law 2026 — Special provisions governing genetic testing on minors, requiring dual parental or legal guardian consent and a court order where applicable.
- UAE Personal Data Protection Law (PDPL) — All genomic data is classified as sensitive personal data, stored on encrypted servers within UAE territory, and never shared with third parties without explicit, revocable consent.
- DHA Facility License 9834453 — Issued by Dubai Health Authority, affirming compliance with clinical laboratory standards.
- ISO 9001:2015 Certification (INT/EGQ/2509DA/3139) — Internationally accredited quality management system covering all pre-analytical, analytical, and post-analytical phases.
Genetic data is never sold, de-identified without consent, or transferred outside UAE jurisdiction except where explicitly authorized by the data subject for international research collaboration under PDPL Article 27 safeguards.
5. Methodology & 2026 Medical Coding Standards
Analytical Methodology
Primary: High-Density Single Nucleotide Polymorphism (SNP) Genotyping via Chromosomal Microarray Platform — detecting genome-wide SNPs and copy number variations (CNVs) across all 22 autosomes and the X chromosome at clinically validated cardiovascular risk loci.
Validation: Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS) for targeted confirmation of metabolically significant variants where indicated. This replaces older immunoassay-based confirmation methods and aligns with 2026 international consensus guidelines for genomic laboratory testing.
2026 Medical Coding
| Code Type | Code | Description |
|---|---|---|
| ICD-10-CM | I25.10 | Atherosclerotic heart disease with documented genetic susceptibility |
| ICD-10-CM | Z84.1 | Family history of disorders of the circulatory system |
| ICD-10-CM | I42.8 | Other cardiomyopathies — including genetic/hereditary cardiomyopathy |
| LOINC | 53039-4 | Cardiovascular disease multigene panel — genomic analysis |
6. Patient FAQ & Clinical Guidance
Q1: What is genetic mapping for cardiovascular disorders, and who should consider it?
Genetic mapping for cardiovascular disorders is a comprehensive DNA-based screening test that identifies inherited gene variants linked to heart muscle diseases, electrical rhythm disorders, and lipid metabolism abnormalities. This test is recommended for individuals with a strong family history of premature heart disease, athletes undergoing pre-participation cardiac screening, and patients with unexplained cardiomyopathy or sudden cardiac arrest survivors. In the UAE, it is increasingly utilized by sports scientists and preventive cardiologists to stratify risk in apparently healthy individuals. The 8-week turnaround reflects the depth of genomic analysis and clinical annotation provided.
س1: ما هو التحليل الجيني لاضطرابات القلب والأوعية الدموية ومن هم الأشخاص الذين ينبغي عليهم إجراؤه؟
التحليل الجيني لاضطرابات القلب والأوعية الدموية هو فحص شامل قائم على الحمض النووي يُحدد الطفرات الجينية الموروثة المرتبطة بأمراض عضلة القلب واضطرابات النظم الكهربائية واضطرابات استقلاب الدهون. يُنصح بهذا الفحص للأشخاص الذين لديهم تاريخ عائلي قوي للإصابة بأمراض القلب المبكرة، وللرياضيين الذين يخضعون لفحوصات ما قبل المشاركة الرياضية، وللمرضى الذين يعانون من اعتلال عضلة القلب غير المبرر أو الناجين من السكتة القلبية المفاجئة. في الإمارات العربية المتحدة، يتزايد استخدام هذا الفحص من قبل علماء الرياضة وأطباء القلب الوقائيين لتقييم المخاطر لدى الأفراد الأصحاء ظاهرياً.
Q2: How long does it take to receive genetic cardiovascular mapping results in the UAE?
Results for the full cardiovascular genetic mapping panel are delivered within eight weeks from the date of sample collection at our Dubai laboratory. This comprehensive timeline encompasses DNA extraction, chromosomal microarray hybridization, SNP genotype calling, bioinformatic annotation against the latest ClinVar and gnomAD databases, and final clinical report generation by a board-certified molecular geneticist. Patients receive telephonic post-test clinical guidance from a DHA-licensed cardiologist upon report availability. Expedited processing is not available for this panel due to the analytical rigor required.
س2: كم من الوقت يستغرق الحصول على نتائج التحليل الجيني للقلب والأوعية الدموية في الإمارات؟
تُسلم نتائج التحليل الجيني الشامل للقلب والأوعية الدموية في غضون ثمانية أسابيع من تاريخ جمع العينة في مختبرنا بدبي. يشمل هذا الإطار الزمني الشامل استخلاص الحمض النووي، والتهجين على المصفوفات الدقيقة للكروموسومات، وتحديد الأنماط الجينية الفردية، والتعليق المعلوماتي الحيوي وفق أحدث قواعد بيانات ClinVar وgnomAD، وإعداد التقرير السريري النهائي من قبل أخصائي جينات جزيئية معتمد. يحصل المريض على استشارة هاتفية بعد صدور النتائج من طبيب قلب مرخص من هيئة الصحة بدبي.
Q3: Is genetic mapping for cardiovascular disorders covered by insurance and regulated in the UAE?
Many UAE-based insurance providers now offer coverage for cardiovascular genetic mapping when the is medically indicated by a DHA-licensed cardiologist and pre-authorized through the insurer's prior-approval pathway. Coverage eligibility typically requires documentation of a first-degree relative with premature cardiovascular disease, a personal history of unexplained cardiac events, or participation in elite athletic programs. Our team provides direct billing verification via WhatsApp at +971 54 548 8731. All genetic testing in the UAE is regulated under Federal Decree-Law No. 41 of 2024 and the UAE PDPL, ensuring your genomic data remains confidential, encrypted, and stored exclusively within UAE territory.
س3: هل يغطي التأمين الصحي تكلفة التحليل الجيني لاضطرابات القلب والأوعية الدموية في الإمارات؟
يقدم العديد من مزودي التأمين الصحي في الإمارات تغطية لتكلفة التحليل الجيني للقلب والأوعية الدموية عندما يكون الفحص مطلوباً طبياً من قبل طبيب قلب مرخص من هيئة الصحة بدبي ويتم الحصول على موافقة مسبقة من شركة التأمين. تتطلب أهلية التغطية عادةً توثيق وجود قريب من الدرجة الأولى مصاب بمرض قلبي وعائي مبكر، أو تاريخ شخصي لأحداث قلبية غير مفسرة، أو المشاركة في برامج رياضية نخبوية. يقدم فريقنا خدمة التحقق المباشر من الفوترة عبر الواتساب على الرقم +971 54 548 8731. تخضع جميع الفحوصات الجينية في الإمارات للمرسوم بقانون اتحادي رقم 41 لسنة 2024 وقانون حماية البيانات الشخصية، مما يضمن بقاء بياناتك الجينومية سرية ومشفرة ومخزنة حصراً داخل أراضي الدولة.
Schedule Your Cardiovascular Genetic Mapping — UAE-Wide Home Collection
Our DHA-licensed mobile phlebotomy team serves all seven emirates with ISO-certified cold-chain logistics. Collection available daily from 8:00 AM to 11:00 PM. Same-day collection slots are subject to availability. A completed Genome Mapping Consent Form (Form 26) is mandatory at the time of collection.
Facility License: 9834453 | ISO 9001:2015 (INT/EGQ/2509DA/3139) | DHA-Regulated Clinical Laboratory
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians